And elevated CSGALNACT2 expression had longer survival outcomes in ovarian cancer patients with Paclitaxel or Docetaxel treatment by Kaplan–Meier survival analysis (Fig. 1H, Supplementary Fig. 1B and C). This evidence concerns the gene CSGALNACT2 and ovarian carcinoma.